Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PP1815
- Development stage
- Phase 2
- Lead developer
- PHAXIAM Therapeutics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intraarticular, Topical
01
Overview
PP1815 is a cocktail of three lytic bacteriophages developed by Phaxiam Therapeutics for the treatment of infections caused by *Staphylococcus aureus*. As a phage therapy, it functions by specifically targeting and infecting *S. aureus* cells, including methicillin-resistant strains (MRSA). Upon infection, the phages hijack the bacterial replication machinery to produce new viral particles, ultimately leading to the lysis and death of the host bacterium. PP1815 is primarily being developed for the treatment of prosthetic joint infections (PJI), a condition often complicated by bacterial biofilms that are highly resistant to conventional antibiotics. The therapy is currently being evaluated in the Phase 2 PHAGEO clinical trial, where it is administered locally to the site of infection.
- Other names
- Pherecydes Staphylococcus aureus phagesPhaxiam Staphylococcus aureus phages
Beyond the preview
Go deeper on PP1815.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PP1815.